The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
PD-1
PD-L1
PD-L2
cervical cancer
endometrial cancer
immunotherapy
ovarian cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
accepted:
30
09
2019
entrez:
5
11
2019
pubmed:
5
11
2019
medline:
5
11
2019
Statut:
epublish
Résumé
The programmed death-1 (PD-1, CD279) receptor with its ligands, programmed death ligand 1 (PD-L1, CD274, B7-H1), and programmed death ligand 2 (PD-L2, CD273, B7-DC), are the key players of one of the immune checkpoint pathways inhibiting T-cell activation. PD-L1 and PD-L2 are expressed in different cancer cells and their microenvironment, including infiltrating immune cells. However, their prognostic value is still debated and their role in the tumor microenvironment has not been fully elucidated yet. Considering the importance that cancer immunotherapy with anti-PD-1 and anti-PD-L1 antibodies gained in several tumor types, in this review article we aim to discuss the role of the PD-1/PD-L1/PD-L2 axis in gynecological cancers. PD-1 ligands have been detected in ovarian, cervical, vulvar and uterine cancers, and correlation with prognosis seems dependent from their distribution. About PD-L2, very few reports are available so far in gynecological malignancies, and its role is still not completely understood. Clinical trials using anti-PD-1 or anti-PD-L1 antibodies, but not anti-PD-L2, are currently ongoing, in all types of gynecological cancers. They have shown good safety profiles in a certain cohort of patients, but response rates remain low and many aspects remain controversial. In this review, we propose possible solutions to enhance the clinical efficacy of PD-1 axis targeting therapies. Regarding PD-L2, it might be useful to better clarify its role in order to improve the efficiency of immunotherapy in female malignancies.
Identifiants
pubmed: 31681606
doi: 10.3389/fonc.2019.01073
pmc: PMC6803534
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1073Informations de copyright
Copyright © 2019 Marinelli, Annibali, Aguzzi, Tuyaerts, Amant, Morelli, Santoni, Amantini, Maggi and Nabissi.
Références
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
J Clin Oncol. 2017 Dec 20;35(36):4035-4041
pubmed: 29095678
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Clin Cancer Res. 2016 Feb 1;22(3):680-90
pubmed: 26832745
Oncotarget. 2015 Oct 20;6(32):32484-93
pubmed: 26431490
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):408-415
pubmed: 29195578
J Gynecol Oncol. 2017 Nov;28(6):e77
pubmed: 29027395
Clin Dev Immunol. 2012;2012:656340
pubmed: 22611421
Mod Pathol. 2015 Dec;28(12):1594-602
pubmed: 26403783
Acta Biochim Biophys Sin (Shanghai). 2004 Apr;36(4):284-9
pubmed: 15253154
Int Immunopharmacol. 2017 Nov;52:7-14
pubmed: 28846888
Leukemia. 2016 Feb;30(2):484-91
pubmed: 26239198
J Immunol. 2011 Dec 1;187(11):5606-14
pubmed: 22025548
Oncol Lett. 2018 May;15(5):6457-6468
pubmed: 29616115
Cancer Res. 2013 Dec 1;73(23):6900-12
pubmed: 23975756
Cancer Microenviron. 2011 Dec;4(3):361-75
pubmed: 21626415
Gynecol Oncol. 2017 Jun;145(3):446-452
pubmed: 28347512
Oncoimmunology. 2016 Dec 9;6(2):e1264565
pubmed: 28344870
Oncotarget. 2017 Oct 6;8(54):92890-92903
pubmed: 29190964
Br J Cancer. 2018 Jul;119(1):80-88
pubmed: 29921949
Front Oncol. 2018 Jul 25;8:285
pubmed: 30090763
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Am J Surg Pathol. 2017 Mar;41(3):326-333
pubmed: 27984238
J Exp Med. 2014 May 5;211(5):943-59
pubmed: 24752301
Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):e79-e85
pubmed: 29271789
J Cell Mol Med. 2018 May 31;:
pubmed: 29855141
J Ovarian Res. 2018 May 30;11(1):43
pubmed: 29843813
J Leukoc Biol. 2013 Jul;94(1):41-53
pubmed: 23667165
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Am J Obstet Gynecol. 2016 Jan;214(1):22-30
pubmed: 26212178
Oncotarget. 2017 Dec 31;9(5):5652-5664
pubmed: 29464025
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Cureus. 2018 Apr 23;10(4):e2521
pubmed: 29942724
Cell Stem Cell. 2009 Jul 2;5(1):31-42
pubmed: 19570512
Diagn Pathol. 2017 Jun 17;12(1):45
pubmed: 28623908
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Oncol Lett. 2016 Aug;12(2):944-950
pubmed: 27446374
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8
pubmed: 27069956
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Cancer Treat Rev. 2017 Sep;59:109-116
pubmed: 28800469
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Histopathology. 2019 Jan;74(2):256-268
pubmed: 30067880
Haematologica. 2001 Dec;86(12):1261-9
pubmed: 11726317
J Cancer Res Clin Oncol. 2019 Jun;145(6):1651-1660
pubmed: 30972492
Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12):
pubmed: 29101107
Oncotarget. 2018 Apr 3;9(25):17501-17511
pubmed: 29707124
Virology. 2009 Feb 20;384(2):260-5
pubmed: 19135222
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
pubmed: 15837746
Gynecol Oncol. 2018 May;149(2):381-387
pubmed: 29572029
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510
Int Immunol. 2010 Aug;22(8):651-60
pubmed: 20587542
Front Oncol. 2016 Nov 01;6:233
pubmed: 27847783
PLoS One. 2015 Dec 01;10(12):e0142868
pubmed: 26624896
Gynecol Oncol. 2016 Aug;142(2):349-56
pubmed: 27174875
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Exp Ther Med. 2015 Nov;10(5):1947-1952
pubmed: 26640578
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Hum Pathol. 2018 Apr;74:135-147
pubmed: 29288043
Mod Pathol. 2016 Jul;29(7):753-63
pubmed: 27056074
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Cancer Res. 2014 Nov 15;74(22):6519-30
pubmed: 25267067
J Obstet Gynaecol Res. 2017 Oct;43(10):1602-1612
pubmed: 28833798
Clin Immunol. 2011 Dec;141(3):338-47
pubmed: 21955569
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Oncotarget. 2017 Sep 15;8(52):89903-89912
pubmed: 29163797
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
JAMA Oncol. 2016 Apr;2(4):518-22
pubmed: 26913631
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023